| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5700587 | Clinical Radiology | 2017 | 9 Pages |
Abstract
T3c or greater disease is the strongest risk factor for predicting DFS in colon cancer, and is accurately identified on imaging. T3c+ disease may therefore be the best imaging entry criteria for trials of neoadjuvant treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
C. Hunter, M. Siddiqui, T. Georgiou Delisle, H. Blake, N. Jeyadevan, M. Abulafi, I. Swift, P. Toomey, G. Brown,